David Charles Ihle, 51Worcester, MA

2010026, Oct 21, 2010

Apr 9, 2008

12/595394

David C. Ihle - Branford CT, US
Qin Guo - Waterford CT, US
Kevin Hodgetts - Killingworth CT, US
Jun Yuan - Guilford CT, US

H. Lindbeck A/S - Valby-Copenhagen

A61K 31/5377
C07D 471/04
A61K 31/437
C07D 213/82
A61K 31/44
C07D 487/04
A61K 31/4985
C07D 413/14
A61K 31/519
C07D 401/14
A61K 31/497
C07D 498/10
A61K 31/438
C07D 403/14
A61K 9/12
A61P 29/00
A61P 25/00

424 43, 546121, 514300, 546285, 514355, 546112, 514299, 544350, 514249, 544127, 5142332, 544279, 5142641, 544362, 51425304, 546 19, 514278, 544405, 51425505

Heteroaryl amide analogues are provided, of Formula (I), wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.

2011015, Jun 23, 2011

Dec 21, 2010

12/974311

Neil Wishart - Jefferson MA, US
Theresa Dunstan - Westborough MA, US
Jeremy J. Edmunds - Acton MA, US
Anna M. Ericsson - Shrewsbury MA, US
Catherine R. Ferenz - Belchertown MA, US
Adrian D. Hobson - Shrewsbury MA, US
David C. Ihle - Worcester MA, US
Kent D. Stewart - Gurnee IL, US
Lei Wang - Acton MA, US
Lu Wang - Westborough MA, US

ABBOTT LABORATORIES - Abbott Park IL

A61K 31/397
C07D 401/14
A61K 31/517
A61K 31/496
A61K 31/454
C07D 487/04
A61K 31/53
A61K 31/437
C07D 403/14
A61K 31/416
C07D 471/04
C07D 413/14
A61K 31/5377
A61P 3/10
A61P 17/06
A61P 1/04
A61P 19/02
A61P 35/00

51421021, 544284, 51426622, 51425217, 546199, 514322, 514249, 544183, 514243, 546121, 514300, 5483611, 514406, 544279, 5142641, 544116, 5142348

The invention provides a compound of Formula (I)pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

2012019, Jul 26, 2012

Aug 11, 2008

12/672413

Rajagopal Bakthavatchalam - Madison CT, US
David C. Ihle - Worcester MA, US
Scott M. Capitosti - Perry OH, US
David J. Wustrow - Los Gatos CA, US
Jun Yuan - Boston MA, US

H. LUNDBECK A/S - Valby-Copenhagen

A61K 31/506
C07D 401/14
C07D 413/14
C07D 209/42
C07D 403/06
A61K 31/4439
A61K 31/5377
A61K 31/404
A61K 31/497
A61K 31/444
A61K 31/4178
A61P 29/00
A61P 25/00
A61P 9/00
A61P 27/02
A61P 19/02
A61P 9/10
A61P 1/00
A61P 25/28
A61P 11/06
A61P 11/00
A61P 25/24
A61P 25/22
A61P 25/18
A61P 25/08
C07D 403/04

5142345, 544331, 5462727, 544122, 548492, 544405, 546256, 5483121, 544120, 514275, 514339, 514419, 51425505, 514333, 514397

Compounds, pharmaceutical compositions, and methods of use are disclosed for heteroaryl amide analogues of formula Ia and/or Ib:In certain embodiments, the heteroaryl amide analogues are agonists and/or ligands of dopamine receptors and may be useful, inter alia, for the treatment of a condition responsive to P2Xreceptor modulation, for example, pain, inflammation, a neurological or neurodegenerative disorder, a cardiovascular disorder, an ocular disorder or an immune system disorder.

2012023, Sep 20, 2012

Mar 15, 2012

13/420957

Kevin P. Cusack - Holden MA, US
Thomas D. Gordon - Medway MA, US
David C. Ihle - Worcester MA, US
Martin E. Hayes - Lowell MA, US
Eric C. Breinlinger - Charlton MA, US
Anna M. Ericsson - Shrewsbury MA, US
Bin Li - Ashland MA, US
Lei Wang - Acton MA, US
Gloria Y. Martinez - Shrewsbury MA, US
Andrew Burchat - Shrewsbury MA, US
Adrian D. Hobson - Shrewsbury MA, US
Kelly D. Mullen - Charlton MA, US
Michael Friedman - Brookline MA, US
Michael J. Morytko - Framingham MA, US

ABBOTT LABORATORIES - Abbott Park IL

A61K 31/122
C07D 213/74
A61K 31/44
C07D 401/12
A61K 31/55
C07C 45/61
C07C 45/62
C07D 453/04
A61P 5/00
A61P 25/30
A61P 37/08
A61P 25/28
A61P 7/10
A61P 25/22
A61P 11/06
A61P 37/00
A61P 31/14
A61P 9/00
A61P 13/12
A61P 27/02
A61P 1/16
A61P 1/00
A61P 25/24
A61P 3/10
A61P 27/06
A61P 29/00
A61P 31/18
A61P 9/12
A61P 35/00
A61P 37/02
A61P 5/48
A61P 35/02
A61P 19/04
A61P 25/00
A61P 3/04
A61P 37/06
A61P 19/10
A61P 19/02
A61P 25/16
A61P 17/06
A61P 25/18
A61P 3/00
A61P 1/04
A61P 17/02
C07C 49/755

51421204, 568326, 514680, 546285, 514352, 540522, 568313, 568309, 568312, 546134, 568315, 568311, 568316

The invention provides a compound of Formula (I)pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

2012033, Dec 27, 2012

Apr 27, 2012

13/458101

Kristine E. Frank - Grayslake IL, US
Andrew Burchat - Shrewsbury MA, US
Philip Cox - Grayslake IL, US
David C. Ihle - Worcester MA, US
Kelly D. Mullen - Charlton MA, US
Gagandeep Somal - Framingham MA, US
Anil Vasudevan - Union Grove WI, US
Lu Wang - Westborough MA, US
Noel S. Wilson - Kenosha WI, US

ABBOTT LABORATORIES - Abbott Park IL

C07D 487/14

544251

The invention provides compounds of Formula (I)pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

2018021, Aug 2, 2018

Dec 22, 2017

15/852179

- North Chicago IL, US
Andrew Burchat - Shrewsbury MA, US
Justin D. Dietrich - Lindenhurst IL, US
Michael Friedman - Brookline MA, US
David Ihle - Worcester MA, US
David Kinsman - Ashland MA, US
Kelly Mullen - Charlton MA, US
Augustine T. Osuma - Lindenhurst IL, US
Anil Vasudevan - Lake Forest IL, US
Noel S. Wilson - Kenosha WI, US

C07D 487/04
C07D 519/00
C07D 498/04

The disclosure provides compounds of Formula (I)pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the disclosure are useful for treating immunological and oncological conditions.

2018008, Mar 29, 2018

Aug 7, 2017

15/670708

- North Chicago IL, US
Eric Breinlinger - Charlton MA, US
Justin D. Dietrich - Lindenhurst IL, US
Michael Friedman - Brookline MA, US
David Ihle - Worcester MA, US
Michael Morytko - Framingham MA, US
Kelly Mullen - Charlton MA, US
Augustine Osuma - Lindenhurst IL, US
Gloria Y. LoSchiavo - Worcester MA, US
Noel S. Wilson - Kenosha WI, US

C07D 403/04
C07F 9/6558
C07D 401/14
C07D 413/04
C07D 471/04
C07D 498/04
C07D 491/107
C07D 487/04
C07D 417/14
C07D 417/04
C07D 403/14
C07D 401/04
C07D 413/14
C07D 405/14
C07D 405/04

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.

2016030, Oct 20, 2016

Apr 15, 2016

15/130279

- North Chicago IL, US
Eric Breinlinger - Charlton MA, US
Justin D. Dietrich - Charlton MA, US
Michael Friedman - Brookline MA, US
David Ihle - Worcester MA, US
Michael Morytko - Framingham MA, US
Kelly Mullen - Charlton MA, US
Augustine Osuma - Lindenhurst IL, US
Glora Y. Lo Schiavo - Worcester MA, US
Noel S. Wilson - Kenosha WI, US

C07D 403/04
C07D 403/14
C07D 491/107
C07D 405/14
C07D 487/04
C07D 405/04
C07D 417/14
C07D 401/04
C07D 417/04
C07D 413/04
C07D 471/04
C07F 9/6558
C07D 401/14
C07D 498/04

The disclosure provides indazolone compounds, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the disclosure may be useful for treating immunological and oncological conditions.